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Background: Hepatic resection is a potentially curative therapy for hepatocellular carcinoma (HCC), but
recurrence of disease is very common. Few studies have reported 10-year actual survival rates following
hepatic resection; instead, most have used actuarial measures based on the Kaplan–Meier method. This
systematic review aims to document 10-year actual survival rates and to identify factors significant in
determining prognosis.
Methods: A comprehensive search was undertaken of MEDLINE and EMBASE. Only studies reporting
the absolute number of patients alive at 10 years after first resection for HCC were included; these figures
were used to calculate the actual 10-year survival rate. A qualitative review and analysis of the prognostic
factors identified in the included studies were performed.
Results: Fourteen studies, all of which were retrospective case series, including data on 4197 patients
with HCC were analysed. Ten years following resection, 303 of these patients were alive. The 10-year
actual survival rate was 7.2%, whereas the actuarial survival quoted from the same studies was 26.8%.
Positive prognostic factors included better hepatic function, a wider surgical margin and the absence of
satellite lesions.
Conclusions: The actual long-term survival rate after resection of HCC is significantly inferior to
reported actuarial survival rates. The Kaplan–Meier method of actuarial survival analysis tends to over-
estimate survival outcomes as a result of censorship of data and subgroup analysis.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cause
of cancer worldwide and is the fourth leading cause of cancer-
related death.1 The incidence and prevalence of HCC are highest
in Southeast Asia and West Africa, but are rising in developed
countries.1 Both surgical resection and liver transplantation are
potentially curative treatments for resectable HCC,2 although
95% of HCC patients in Western populations have coexistent
cirrhosis of the liver.3 Even for small and resectable HCC, trans-
plantation is the preferred treatment option as it addresses both
the apparent tumour and tumours that are not yet apparent, and
the underlying cirrhosis.4 However, its usage is limited by the lack
of donor organs.5
Although it has been recommended that direct clinical out-
comes such as overall actual survival should be used as an end-
point in studies of HCC,6 actuarial survival measures remain the
most often reported. The Kaplan–Meier method of actuarial sur-
vival analysis was first published in the 1950s as a way of estimat-
ing outcomes with incomplete data.7 The major risk for bias
associated with this method is a result of the process of censoring,
whereby certain patients are excluded from the final analysis.8 The
reasons for exclusion may include loss to follow-up, perioperative
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mortality or death from other causes. The Kaplan–Meier method
also allows subset analysis to be used and then applied to the
group as a whole.When applied to survival data, these approaches
can lead to a gross overestimation of survival, which is misleading
for both clinicians and patients.
The primary purpose of this study was to estimate, by a sys-
tematic review of published data, actual 10-year survival following
resection of HCC. The secondary aim was to establish prognostic
factors associated with improved survival.
Materials and methods
Literature search
A comprehensive search of theMEDLINE and EMBASE databases
was undertaken in the first week of November 2011. The search
strategy is provided in Appendix A1. A manual search of the ref-
erences of the retrieved studies was performed. In the case of
duplicate reporting of the same study population, the report that
included the largest amount of outcome data was included.
Inclusion and exclusion criteria
Studies were included if they examined 10-year survival following
resection of HCC in adults and quoted an actual number or
percentage of survivors, or included sufficient data for these to be
determined. Studies were excluded if they reported data for fewer
than five patients, if 10-year follow-up was not complete, if the
data had been previously published, or the information reported
was insufficient to calculate a 10-year actual survival.
Outcome measures
In order to determine the primary outcome measure of 10-year
survival, the total number of patients alive at 10 years was divided
by the total number of patients included in the study. The second-
ary outcome measures sought in each study were the prognostic
factors associated with survival. Because of the heterogeneity of
the data reported in each study, formal meta-regression was not
feasible. In each study, the factors reported to have a statistically
significant association with survival were tabulated. Whether the
factor was statistically significant using univariate or multivariate
analysis, or both, was documented. These factors were then quali-
tatively described. Some factors were reported in the original
studies with a specific numeric cut-off value (such as level of
albumin or age). In the review, these were broadly categorized
(increased albumin or greater age) to allow the otherwise hetero-
geneous data to be presented and analysed coherently.
Results
Description of studies
The searches of MEDLINE and EMBASE yielded 966 and 2327
publications, respectively. The combination of these searches pro-
duced 3293 manuscripts for analysis. No additional studies were
identified after reference searching. After excluding duplicate
studies, studies that repeated previously published data and
studies that did not include the absolute number of survivors at
10 years, 14 studies were suitable for inclusion in this review. All
14 studies were retrospective analyses. Publication dates ranged
from 1987 to 2009.
Patient characteristics
Patient characteristics are summarized in Table 1. The total
number of patients in these studies was 4197. The median patient
age at study enrolment was 60 years (range: 50–64 years). Overall,
84.3% (2811 of the 3335 patients for whom data on sex were
provided) of the patients were male and 78.1% (2052 of the 2626
patients for whom cirrhosis data were provided) had cirrhosis.
Patient characteristics were often collated after censorship had
been applied and therefore were not reflective of the initial patient
population.
Study heterogeneity
There were significant variations in the populations included in
the studies. Many of the studies included only patients with well-
preserved liver function. Fukuda et al. included only patients with
Child–Pugh class A liver function who underwent curative resec-
tion,9 whereas Lee et al. did not perform resection in patients with
‘evidence of hepatic decompensation’.10 The criteria for inclusion
in the study by Pandey et al. were a lesion of  10 cm and Child–
Pugh class A liver function.11 Chen et al. exclusively studied people
with lesions measuring >10 cm and Child–Pugh class A or B liver
function; neither Chen et al. nor Nagasue et al. performed analysis
of prognostic factors after 10 years.12,13 The 2003 study by Zhou
et al. was limited to HCC tumours of > 10 cm, whereas their 2001
study referred to HCC measuring > 5 cm.14,15 Both Shimada et al.
and Hanazaki et al. limited their analysis to patients who under-
went potentially curative hepatectomy,16,17 but Shirabe et al. did
not place any restrictions on patient selection.18
Primary study outcome
The number of patients in each study and the actual and actuarial
survival percentages are summarized in Table 2. Of the 4197
patients included in the analysis, 303 patients were alive at
10 years, which equates to an actual 10-year survival rate of 7.2%.
Actuarial survival figures in these studies ranged from 10.5% to
46.3%.15,17 The overall rate determined across the 14 studies was
26.8%. Four studies9,10,16,19 indicated the proportion of patients
whose fate at 10 years (whether dead or alive) was known. These
four studies included data pertaining to 862 patients, the 10-year
outcome of 750 (87.0%) of whom was known (Table 2). Eleven
studies stated the rate of perioperative mortality within 3 months
of surgery. In these, overall perioperative mortality was 5.0% (196
of 3912 patients). The difference between actual and actuarial
survival was calculated for each study (Table 2) in order to deter-
mine whether associations could be discerned between a large
difference in survival measures and country of origin of study,
prevalence of cirrhosis, perioperative mortality or completeness
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Table 1 Patient characteristics
Study Year City and country
of institution
Patients,
n
Gender,
male : female
Age,
years,
median
Age,
years,
mean
Cirrhosis,
+ : -
HBs Ag,
+ : -
HCV Ab,
+ : -
Fortner & Fong20 2009 New York, USA 70 a a a a a a
Fukuda et al. 9 2007 Hiroshima, Japan 145 116 : 29 61 a a 29 : 112b 68 : 41b
Pandey et al.11 2007 Singapore 166 143 : 23 55 a 80 : 86 131 : 35 3 : 163
Hashimoto et al.19 2007 Fukuoka, Japan 91 66 : 19b a 61b a 16 : 69b 64 : 21b
Shimada et al.16 2005 Tokyo, Japan 578 383 : 98b a 60b a 75 : 406b 286 : 144b
Chen et al.12 2004 Wuhan, China 525 471 : 54 a 37 480 : 45 366 : 159 a
Zhou et al.14 2003 Shanghai, China 621 a a a a a a
Zhou et al.15 2001 Shanghai, China 1 000 881 : 119 50 a 888 : 112 721 : 218b a
Hanazaki et al.17 2000 Matsumoto, Japan 386 293 : 93 64 63 202 : 184 86 : 300 172 : 214
Shirabe et al.18 1998 Fukuoka, Japan 142 81 : 15b a 56b 72 : 31b 16 : 87b a
Lee et al.10 1996 Taiwan 48 42 : 6 a 55 40 : 8 a a
Nagasue et al.13 1993 Izmo, Japan 229 188 : 41 a 61 177 : 52 a a
Choi et al.21 1990 Hong Kong 174 147 : 27 a 54 113 : 56b 132 : 42 a
Sesto et al.22 1987 Cleveland, USA 22 a a a a a a
Total 4 197 2 811 : 524 55.9  4.2c 2 052 : 574 1 572 : 1 428 593 : 583
aThis information was analysed after the exclusion of some patients and therefore does not reflect the total patient number.
bThe analysis of patient characteristics was either incomplete or made after the exclusion of some patients and therefore does not reflect the total
patient number or the initial patient population.
cMean of mean ages  standard error of the mean.
HBs Ag+, positive hepatitis B surface antigen; HCV Ab+, positive hepatitis C antibody.
Table 2 Survival data across the 4197 patients included in the 14 studies
Study Patients,
n
10-year
survivors, n
Patients
accounted
for at 10
years, n (%)
Perioperative
mortality within
3 months, n (%)
Actual
survival, %
Quoted
actuarial
survival, %
Difference
between actual
and actuarial
survival, %
Fortner & Fong20 70 15 NS 9 (12.9)a 21.4 24.0 2.6
Fukuda et al. 9 145 29 145 (100) NS 20.0 26.9 6.9
Pandey et al.11 166 4 NS 5 (3.0)a 2.4 25.6 23.2
Hashimoto et al.19 91 19 89 (97.8) 3 (3.3)a 22.4 b b
Shimada et al.16 578 105 468 (80.9) 18 (3.1)a 18.2 21.8 3.6
Chen et al.12 525 15 NS 14 (2.7)c 2.9 b b
Zhou et al.14 621 11 NS 28 (4.5)a 1.8 17.5 15.7
Zhou et al.15 1 000 60 NS 15 (1.5)a 6.0 46.3 40.3
Hanazaki et al.17 386 7 NS 27 (7.0)d 1.8 10.5 8.7
Shirabe et al.18 142 12 NS 39 (27.5)a 8.5 11.7 3.3
Lee et al.10 48 15 48 (100) NS 31.0 b b
Nagasue et al.13 229 2 NS 24 (10.5)c 0.9 19.4 18.5
Choi et al.21 174 8 NS 23 (13.2)c 4.6 b b
Sesto et al.22 22 1 NS NS 3.5 12.0 8.6
Total 4 197 303 87.0 4.9% 7.2  9.9 26.8  10.5e
aPerioperative mortality excluded from actuarial survival calculation.
bActuarial survival not quoted.
cAnalysis of perioperative mortality with respect to actuarial survival calculation not stated.
dPerioperative mortality included in actuarial survival calculation.
eOverall actuarial survival calculated from studies in which these data were provided or could be calculated.
NS, not stated or cannot be derived from data presented.
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of follow-up for 10 years. However, the data were insufficient to
reliably describe any such patterns.
Secondary study outcomes
Univariate analysis demonstrated a number of patient, tumour
and treatment prognostic factors associated with survival out-
comes. Patient factors associated with survival outcomes are
described in Table 3. Tumour and treatment factors are outlined
in Tables 4 and 5, respectively. On multivariate analysis the fol-
lowing factors showed a positive association with survival: the
absence of or a less severe stage of cirrhosis; female sex; lower
serum g-glutamyl transpeptidase (g-GPT); lower serum bilirubin;
non-cancerous liver parenchyma; higher serum albumin; a lower
indocyanine green retention rate at 15 min (ICG15), and younger
age.9–11,15,16,19 Significant positive prognostic tumour factors were:
the absence of satellite lesions; the absence of intrahepatic
metastases, vascular invasion or portal vein invasion, and the
absence of capsular invasion.9–11,15,16 The only significant treat-
ment factor, on multivariate analysis, was resection margin,
whereby a margin of >10 mm was associated with a better
prognosis.10
Discussion
This review identified an overall 10-year actual survival rate fol-
lowing resection of HCC of 7.2%, which is lower than the actu-
arial figures quoted in the studies to which the review refers. The
difference may be understood by considering the way in which
actuarial survival is calculated. It is a result of subset analysis and
censorship of outcomes for certain patients. For example, in the
study by Shimada et al., 578 patients underwent potentially cura-
tive hepatectomy for HCC.16 Of these, 97 patients were excluded
from the final analysis as seven died in hospital, 11 died within
1 month of surgery, 14 died from non-cancer causes, eight were
lost to follow-up and 57 underwent palliative resection. This gives
a surgical mortality of 3.1% (18/578 patients). The number of
patients alive at 10 years after resection was 105, giving an actu-
Table 3 Univariate analysis of prognostic patient factors
Study Inc age Male Cirrhosis Child A HBs Ag + HCV Ab + Lower Alb Higher ICGR15 Higher AFP
Fukuda et al.9 NS NEG NEG N/A NS NS NS NEG NS
Pandey et al.11 NS NS NEG N/A a a a a NS
Hashimoto et al.19 NS NS a a NS NS NEG a a
Shimada et al.16 NEG a a a a NEG a NEG a
Zhou et al.14 a a a a a a a a a
Zhou et al.15 a a a a a a a a a
Hanazaki et al.17 a a NEG POS a a a NEG a
Shirabe et al.18 NS NS NS a NEG a NEG NEG a
Lee et al.10 NS NS NS a a a a a NS
aAnalysis not performed or not specifically identified.
NS, not statistically significant; POS, positive prognostic factor; NEG, negative prognostic factor; N/A, not applicable; Child A, Child–Pugh class A
liver function; HBs Ag+, positive hepatitis B surface antigen; HCV Ab+, positive hepatitis C antibody; ICGR15, indocyanine green dye retention at
15 minutes; AFP, alpha fetoprotein.
Table 4 Univariate analysis of prognostic tumour factors
Study Number of
tumours
(multi)
Tumour
size
(larger)
Differentiation
(less)
Vascular
invasion
(histopathology)
Intrahepatic
metastases
Capsule
invasion
Portal
vein
invasion
Capsule
presence
Fukuda et al. 9 NS NS (30 mm) NS NEG NEG NS a a
Pandey et al.11 NEG NEG (?limit) NEG NEG a NS a a
Hashimoto et al.19 NS NS a NS a a a a
Shimada et al.16 NEG NS a a NEG a NEG a
Zhou et al.14 NEG N/A a a a a NEG POS
Zhou et al.15 NEG NEG a a a a NEG POS
Hanazaki et al.17 a a a NEG a a a a
Shirabe18et al. a NS NS a NS NS NS NS
Lee et al.10 a NS a a a NEG a a
aAnalysis not performed or not specifically identified.
NS, not significant; POS, positive prognostic factor; NEG, negative prognostic factor.
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arial survival percentage of 21.8% (105/481 patients). The actual
survival as indicated by the number of patients alive at 10 years
divided by the initial number of patients enrolled was 18.2%
(105/578 patients). By excluding patients who suffered postopera-
tive mortality and those who died from other causes, the survival
quoted in these manuscripts reflects survival probability only if a
patient did not die perioperatively, did not die from other causes
and did not undergo the conversion of a curative to a palliative
procedure once the operation had commenced and the extent of
disease had been discovered. The actuarial survival figure is thus
not reflective of true 10-year survival in all patients who under-
went initial resection.
The actual survival outcomes in this study are reflective of a
worst-case scenario, as only patients who were proven to be alive
at 10 years were deemed to be actual 10-year survivors. Patients
who were lost to follow-up or who were alive at the conclusion of
the study but had not been followed up for 10 years were not
included in the final analysis of actual survival, which may lead to
an overestimation of mortality. In the actuarial survival calcula-
tions, these patients are censored and are assumed to have the
same survival prospects as those who continued under follow-up.7
This may lead to an overly optimistic estimate of survival. In only
four studies was the comprehensiveness of 10-year follow-up
stated. In these, the fate of 87.0% of patients was known at
10 years. Given that these data were available for fewer than one
quarter of the cohort in this analysis, the extent to which the
difference between actual and actuarial survival can be accounted
for by incomplete follow-up is unknown. Nevertheless, most
studies censored data for reasons other than incomplete follow-
up, such as perioperative mortality or death from other causes. It
is likely that the most accurate survival figure will lie somewhere
between the pessimistic calculation of actual survival and the
optimistic actuarial survival figures that are more widely quoted.
It was not possible to perform a meta-analysis of the data in
these studies because of the heterogeneous nature of the patient
populations, differing qualities of outcome reporting and the lack
individual patient data provided in the manuscripts. No reliable
conclusions could be drawn when the studies were analysed
according to the difference between actual and actuarial survival
to determine whether there might be an association with a wide
range in this outcome and comorbid cirrhosis, perioperative mor-
tality or completeness of follow-up to 10 years. This analysis was
made impossible by the incomplete reporting of data in each
category and the small number of studies. It may be that a large
proportion of the difference reflects censorship resulting from
incomplete follow-up. However, in the studies that reported these
data, the vast majority (87.0%) of patients were followed until
death or 10 years post-surgery.
It should be noted that there was a lack of agreement regarding
the prognostic significance of many patient, tumour and treat-
ment factors. In particular, factors determined on univariate
analysis as not significant in some studies were found by others to
be significant on multivariate analysis. An example of this is
female sex. Fukuda et al.9 found it to be a positive factor on mul-
tivariate analysis, but four studies deemed female sex to be non-
significant on univariate analysis.10,11,18,19 These differences make it
difficult to assess the true significance of factors in relation to
survival. Further long-term follow-up and multicentre analysis
are required to better define survival outcomes and factors with
prognostic significance. In order to distinguish the effect of HCC
from that of its common comorbidity, cirrhosis, it would be nec-
essary to perform cohort studies with age- and disease-matched
controls. Prognostic factors could then be increasingly considered
in planning treatment for patients.
Actual long-term survival after resection of HCC is poorer than
the actuarial figures reported imply. The significance of the dif-
ference between actuarial and actual survival data pertains to the
expectations of clinicians and patients when discussing treatment
options. Although Kaplan–Meier survival analysis is a legitimate
and necessary tool for providing survival estimates, especially
when comparing groups in controlled clinical trials, for most
patients and many clinicians it can lead to a significant overesti-
Table 5 Univariate analysis of prognostic treatment factors
Study Preoperative
TACE
Resection:
limited vs.
anatomical
Surgical
margin
positive
Blood
transfusion
Blood
loss
(higher)
Resection
intent: curative
vs. palliative
Fukuda et al.9 NS NS 5 mm NS NS a a
Pandey et al.11 NS NS NS a a a
Hashimoto et al.19 a a NS NS a a
Shimada et al.16 NS NEG NEG a a a
Zhou et al.14 a a a a a POS
Zhou et al.15 a NS NEG a a a
Hanazaki et al.17 NS NS >5 mm POS a NEG (>1500 ml) a
Shirabe et al.18 a a a a a a
Lee et al.10 a a >10 mm POS a a a
aAnalysis not performed or not specifically identified.
NS, not significant; POS, positive prognostic factor; NEG, negative prognostic factor; TACE, transarterial chemoembolization.
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mation of the utility of treatment and likely outcomes of surgery.
A patient who is informed that she has a 20% chance of survival
for 10 years post-surgery is unlikely to interpret this as meaning
that she has a 20% chance of survival only if she does not die
perioperatively, does not die from other diseases and if her cura-
tive procedure is not deemed palliative once the operation com-
mences. The actual survival rate is the more intuitive and
appropriate measure to use when discussing treatment options
with patients.
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Appendix A1
Search strategy for MEDLINE
1 exp hepatectomy/ (19 350)
2 liver resection.mp. (4278)
3 exp carcinoma, hepatocellular/ (51 560)
4 exp disease-free survival/ or exp survival/ or exp survival rate/
(137 147)
5 ten-year survival.mp. (640)
6 4 or 5 (137 607)
7 1 or 2 (20 865)
8 3 and 7 (3909)
9 6 and 8 (968)
10 limit 9 to humans (966)
Search strategy for EMBASE
1 exp liver resection/ (28 236)
2 exp liver cell carcinoma/ (67 745)
3 exp overall survival/ or exp survival/ or exp event-free
survival/ (415 045)
4 ten-year survival.mp. (705)
5 hepatocellular carcinoma.mp. (45 885)
6 hepatectomy.mp. (15 749)
7 1 or 6 (31 418)
8 2 or 5 (74 349)
9 7 and 8 (6795)
10 3 or 4 (415 304)
11 9 and 10 (2566)
12 limit 11 to human (2327)
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